Cover Image
市場調查報告書

全球疼痛治療藥市場,第5版:市場趨勢、R&D考察

The Global Pain Therapeutics Market, 5th Edition: Market Trends & R&D Insights

出版商 Arrowhead Publishers 商品編碼 363527
出版日期 內容資訊 英文 536 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全球疼痛治療藥市場,第5版:市場趨勢、R&D考察 The Global Pain Therapeutics Market, 5th Edition: Market Trends & R&D Insights
出版日期: 2015年12月12日 內容資訊: 英文 536 Pages
簡介

全球15億人罹患中度到重度的慢性疼痛。在美國障礙的原因第1名是疼痛,影響1億1,600萬個成人,超過心臟疾病,癌症及糖尿病的總合。美國的慢性疼痛的年度成本龐大,從5,600億提高到6,350億美元。

本報告提供全球疼痛治療藥市場相關調查,趨勢和課題,進入該領域的主要企業簡介,臨床開發階段及已上市的主要產品相關最新趨勢的彙整。

第1章 摘要整理

第2章 疼痛:疾病的背景

  • 疼痛的簡介
  • 疼痛的分類
  • 疼痛的病理學
  • 免疫系和疼痛
  • 疼痛與遺傳學
  • 疼痛的主觀的性質
  • 疼痛的全世界的影響

第3章 疼痛管理:WHO的疼痛治療藥分類、治療指南

  • WHO的疼痛治療藥的分類概要
  • M01A 非類固醇消炎劑 (NSAID)
  • M01B 抗發炎性/抗風濕藥的組合
  • N01A 全身麻醉劑
  • N01B 局部麻醉劑
  • N02A 麻醉劑止痛藥
  • N02B 非麻醉劑止痛藥
  • N02C 抗偏頭痛藥
  • Arrowhead的止痛藥分類系統
  • WHO的疼痛管理指南

第4章 手術後疼痛市場

  • 手術後疼痛概要
  • 手術後疼痛的流行病學
  • 術後止痛管理
  • 主力品牌
  • 未滿足需求
  • 開發平台分析
  • 市場說明

第5章 神經性疼痛市場

  • 神經性疼痛概要
  • 神經性疼痛的流行病學
  • 神經性疼痛的治療管理
  • 主力品牌
  • 未滿足需求
  • 開發平台分析
  • 市場說明

第6章 纖維肌痛市場

  • 纖維肌痛概要
  • 纖維肌痛的流行病學
  • 纖維肌痛的治療管理
  • 主力品牌
  • 未滿足需求
  • 開發平台分析
  • 市場說明

第7章 關節痛市場

  • 關節痛概要
  • 關節痛的流行病學
  • 關節痛的治療管理
  • 主力品牌
  • 未滿足需求
  • 開發平台分析
  • 市場說明

第8章 偏頭痛市場

  • 偏頭痛概要
  • 偏頭痛的流行病學
  • 偏頭痛的治療管理
  • 主力品牌
  • Impax Laboratories/AstraZeneca的Zomig (zolmitriptan)
  • 未滿足需求
  • 開發平台分析
  • 市場說明

第9章 癌症疼痛市場

  • 癌症疼痛概要
  • 癌症疼痛的流行病學
  • 癌症止痛管理
  • 主力品牌
  • 未滿足需求
  • 開發平台分析
  • 市場說明

第10章 腰痛市場

  • 腰痛概要
  • 腰痛的流行病學
  • 腰痛的治療管理
  • 主力品牌
  • 未滿足需求
  • 開發平台分析
  • 市場說明

第11章 疼痛治療藥的研究開發趨勢

  • 簡介:變化的需求
  • 臨床實驗概要
  • 以止痛藥臨床實驗為中心的問題
  • R&D的生物標記
  • 止痛標的選擇、評估
  • 動物疼痛模式
  • 健康的人體中實驗疼痛模式
  • 功能性影像技術
  • 雷射多普勒血流計 (LDF)
  • 對抗FDA的類鴉片物質的濫用的配合措施

第12章 疼痛治療藥市場上未滿足需求

  • 目前止痛藥的需求高漲中的臨床性效果
  • 目前疼痛治療藥的安全性不穩定
  • 類鴉片物質的濫用
  • 忽視某種程度的疼痛患者人口
  • 投藥療法的改善
  • 便利性高的給藥途徑
  • 動物疼痛模式的有效性
  • 疼痛評估模式的可靠性

第13章 對疼痛治療藥開發平台的關注

第14章 疼痛治療藥市場分析

第15章 企業概要

第16章 參考文獻

圖表清單

目錄

Pain continues to represent major clinical, social and economic challenges. Globally, 1.5 billion people suffer from moderate to severe chronic pain. Pain is the leading cause of disability in the US, affecting 116 million adults, more than heart disease, cancer and diabetes combined. The US annual cost of chronic pain ranges from a colossal $560 to $635 billion.

Despite two decades of intensive R&D effort, commercialization of new products has been limited. Current analgesics only provide modest pain relief, frequently carry black box safety warnings and are susceptible to abuse. Indeed, in the US, opioid abuse is described as a deadly epidemic.

In recent years, key blockbuster products OxyContin, Cymbalta, Celebrex and Lidoderm have faced patent loss. With Pfizer's Lyrica patent expiry looming in 2018, the pain market will suffer further generic threat. Nevertheless, the hotly anticipated arrival of novel abuse-deterrent opioids and monoclonal antibodies such as NGF, CGRP and IL-6 inhibitors will drive future market growth.

This in-depth, quality report delivers:

  • Analysis of seven major painful conditions examining epidemiology in the seven major markets, therapeutic management overview, unmet needs and clinical/commercial pipeline analysis of each condition to maximize your product's commercial success
  • Identification of the major challenges within pain R&D including unmet needs, clinical trial design, alternative R&D approaches, potential pain biomarkers, animal pain models, functional imaging techniques and regulatory hurdles
  • An assessment of the financial pain market with forecasts to 2020 for over 70 leading branded analgesic products and key pipeline candidates
  • Analysis of seven major painful conditions examining epidemiology in the seven major markets, therapeutic management overview, unmet needs and clinical/commercial pipeline analysis of each condition to maximize your product's commercial success
  • Identification of the major challenges within pain R&D including unmet needs, clinical trial design, alternative R&D approaches, potential pain biomarkers, animal pain models, functional imaging techniques and regulatory hurdles
  • An assessment of the financial pain market with forecasts to 2020 for over 70 leading branded analgesic products and key pipeline candidates

Report highlights:

The pain therapeutics market is crowded and heavily genericized. In 2015, the leading branded pain therapeutics market is worth $11.3 billion, down 13.5% from 2014 total revenues of $13.1 billion.

Opioids form the backbone of pain management. This trend is set to continue over the coming years thanks to their continued superior analgesic activity. Physicians should become increasingly more confident in prescribing opioids due the arrival of abuse-deterrent formulations. By 2020, the leading branded opioids will generate over $6.6 billion in worldwide revenues.

Pain R&D is challenging, expensive and reliant on subjective outcome measures. Therefore, industry must revise their R&D strategies to gain success in this market. The FDA's 2014 Draft Guidance for Industry Analgesic Indications: Developing Drug and Biological Products should provide some clarity for pain developers, as this was indeed the first guidance update in over 20 years.

Purchase of Arrowhead's ‘Global Pain Therapeutics Market, 5th Edition: Market Trends and R&D Insights 2015 ’ will enable you to:

  • Assess opportunities and challenges influencing strategic pain R&D
  • Identify leading branded pain therapeutics and key pipeline candidates in late-stage development based on sales forecasts to 2020 to maximize your products commercial potential
  • Gain an impartial perspective of strategies that can be used to enhance your products performance in the pain market

Key questions answered by Arrowhead's ‘Global Pain Therapeutics Market, 5th Edition: Market Trends and R&D Insights 2015 ’ include:

  • What are the major unmet needs in the current pain market?
  • What are the leading potential pain biomarkers?
  • What are the major challenges involved in the pain market and how can they be overcome?
  • Who are the key players involved in the pain market and what business models are they using to raise company performance?
  • How can players optimize strategic pain R&D to maximize commercial success?
  • What recommendations does Arrowhead provide for successful pain R&D?
  • What are the leading branded pain therapeutics available on the market?
  • What are the key leading therapeutic candidates in the pain pipeline?
  • How much revenue will the leading branded analgesic products reach by 2020?
  • How much revenue will the key pipeline drug candidates reach by 2020?
  • What does the future hold for the pain market?

Table of Contents

1. EXECUTIVE SUMMARY

  • 1.1. Scope of Global Pain Therapeutics Market, 5th Edition
  • 1.2. Methodology of Global Pain Therapeutics Market, 5th Edition
  • 1.3. The Epidemiology of Pain in the Seven Major Markets
  • 1.4. Unmet Needs in the Pain Therapeutics Market
  • 1.5. Pain Therapeutics Pipeline Analysis
  • 1.6. Pain Therapeutics Market Analysis

2. PAIN: DISEASE BACKGROUND

  • 2.1. An Introduction to Pain
  • 2.2. The Classification of Pain
    • 2.2.1. Acute Pain
    • 2.2.2. Chronic Pain
  • 2.3. The Pathophysiology of Pain
    • 2.3.1. The Pain Pathway
    • 2.3.2. The Modulation of the Pain Signal
    • 2.3.3. Referred Pain
  • 2.4. The Immune System and Pain
    • 2.4.1. Nerve Growth Factor (NGF)
    • 2.4.2. Brain Derived Neurotrophic Factor (BDNF)
    • 2.4.3. Nitrous Oxide (NO)
    • 2.4.4. Tumor Necrosis Factor (TNF)
    • 2.4.5. Interleukin-1(IL-1)
    • 2.4.6. Interleukin-6(IL-6)
    • 2.4.7. Glutamate
  • 2.5. Pain and Genetics
  • 2.6. The Subjective Nature of Pain
    • 2.6.1. The Evaluation of Pain
  • 2.7. The Global Impact of Pain
    • 2.7.1. The Financial Impact of Pain

3. MANAGING PAIN: WHO'S PAIN THERAPEUTICS CLASSES AND TREATMENT GUIDELINES

  • 3.1. Overview of the WHO'S Pain Therapeutics Classification
  • 3.2. M01A Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
  • 3.3. M01B Anti-Inflammatory/Anti-Rheumatic Agents in Combination
  • 3.4. N01A General Anesthetics
  • 3.5. N01B Local Anesthetics
  • 3.6. N02A Narcotic Analgesics
  • 3.7. N02B Non-Narcotic Analgesics
  • 3.8. N02C Anti-Migraine Preparations
  • 3.9. Arrowhead's Analgesic Drug Classification System
  • 3.10. WHO Pain Management Guidelines

4. THE POSTOPERATIVE PAIN MARKET

  • 4.1. Overview of Postoperative Pain
  • 4.2. Epidemiology of Postoperative Pain
  • 4.3. The Therapeutic Management of Postoperative Pain
    • 4.3.1. Epidural Local Anesthetics Used in Postoperative Pain
    • 4.3.2. Strong Opioids Used in Postoperative Pain
    • 4.3.3. Weak Opioids Used in Postoperative Pain
    • 4.3.4. NSAIDs Used in Postoperative Pain
    • 4.3.5. Multi-Modal Analgesia Used in Postoperative Pain
  • 4.4. Leading Brand Products in the Postoperative Pain Market
    • 4.4.1. Janssen Pharmaceuticals' Duragesic (transdermal fentanyl)
    • 4.4.2. Pacira Pharma's Exparel (bupivacaine liposome injection)
    • 4.4.3. Hospira Inc's Dyloject (Dicofenac Injection)
  • 4.5. Unmet Needs in the Postoperative Pain Market
  • 4.6. Postoperative Pain Therapeutics Pipeline Analysis
    • 4.6.1. Durect Corporation's Posidur (SABER-bupivacaine)
    • 4.6.2. Trevena's TRV130
    • 4.6.3. Adynxx's AYX1
    • 4.6.4. Yichang Humanwell's Morphine 6-gluconaride (M6G, intravenous morphine)
  • 4.7. Postoperative Pain Therapeutics Market Commentary

5. THE NEUROPATHIC PAIN MARKET

  • 5.1. Overview of Neuropathic Pain
  • 5.2. Epidemiology of Neuropathic Pain
  • 5.3. The Therapeutic Management of Neuropathic Pain
    • 5.3.1. Topical Lidocaine Used in Neuropathic Pain
    • 5.3.2. Antidepressants Used in Neuropathic Pain
    • 5.3.3. Opioids Used in Neuropathic Pain
  • 5.4. Leading Brand Products in the Neuropathic Pain Market
    • 5.4.1. Endo Pharmaceuticals' Lidoderm (lidocaine 5% Patch)
    • 5.4.2. Pfizer's Lyrica (pregablin)
    • 5.4.3. Eli Lilly's Cymbalta (duloxetine)
    • 5.4.4. Pfizer's Neurontin (gabapentin)
    • 5.4.5. Johnson&Johnson/Depomed's Nucynta ER (tapentadol-er)
    • 5.4.6. Acorda Therapeutics/Astellas Pharma's Qutenza (capsaicin 8% patch)
    • 5.4.7. Depomed/Abbott's Gralise (gabapentin-er)
  • 5.5. Unmet Needs in the Neuropathic Pain Market
  • 5.6. Neuropathic Pain Therapeutics Pipeline Analysis
    • 5.6.1. BioDelivery Sciences International's Topical Clonidine Gel
    • 5.6.2. Daiichi Sankyo's Mirogabalin (DS-5565)
    • 5.6.3. Immune Pharmaceuticals' AmiKet (amitriptyline/ketamine)
    • 5.6.4. Biogen's CNV-1014802
    • 5.6.5. Impax Laboratories/Durect Corps's Eladur (Transdur-Bupivacaine Patch)
    • 5.6.6. Convergence Pharmaceuticals/Calchan's CNV-2197944
    • 5.6.7. Novartis/Spinifex Pharmaceuticals'EMA401
    • 5.6.8. Pfizer's Lyrica-CR (pregabalin controlled-release)
  • 5.7. Neuropathic Pain Therapeutics Market Commentary

6. THE FIBROMYALGIA MARKET

  • 6.1. Fibromyalgia Overview
  • 6.2. Epidemiology of Fibromyalgia
  • 6.3. The Therapeutic Management of Fibromyalgia Pain
    • 6.3.1. Analgesics Used in Fibromyalgia
    • 6.3.2. Antidepressants Used in Fibromyalgia
    • 6.3.3. Muscle Relaxants Used in Fibromyalgia
    • 6.3.4. Sleep Modifiers Used in Fibromyalgia
    • 6.3.5. Anxiety Medications Used in Fibromyalgia
    • 6.3.6. Anticonvulsants Used in Fibromyalgia
    • 6.3.7. Antibiotics Used in Fibromyalgia
  • 6.4. Leading Brands in the Fibromyalgia Pain Market
    • 6.4.1. Pfizer's Lyrica (pregabalin)
    • 6.4.2. Allergen/Forest Laboratories ‘Savella (milnacipran)
    • 6.4.3. Eli Lilly's Cymbalta (duloxetine)
  • 6.5. Unmet Needs in Fibromyalgia Pain Market
  • 6.6. Fibromyalgia Pain Pipeline Analysis
    • 6.6.1. Daiichi Sankyo's Mirogabalin (DS-5565)
    • 6.6.2. Tonix Pharmaceuticals' TNX-102 SL
    • 6.6.3. Theravance Biopharmas' TD-9855
    • 6.6.4. Pfizer's Lyrica-CR (pregablin controlled-release)
  • 6.7. Fibromyalgia Pain Market Commentary

7. THE ARTHRITIC PAIN MARKET

  • 7.1. Arthritis Overview
  • 7.2. Epidemiology of Arthritic Pain
  • 7.3. The Therapeutic Management of Arthritic Pain
    • 7.3.1. Acetaminophen used in Arthritis
    • 7.3.2. NSAIDs Used in Arthritis
    • 7.3.3. COX-2 Inhibitors Used in Arthritis
    • 7.3.4. Disease Modifying Anti-Rheumatic Drugs (DMARDs) Used in Arthritis
    • 7.3.5. Biologic Disease Modifying Anti-inflammatory Drugs Used in Arthritis
    • 7.3.6. Corticosteroids Used in Arthritis
    • 7.3.7. Immunosuppressants used in Arthritis
  • 7.4. Leading Brands in the Arthritic Pain Market
    • 7.4.1. Horizon Pharma/AstraZeneca/Pozen 's Vimovo (naproxen/esomeprazole)
    • 7.4.2. Pfizer Celebrex (celecoxib)
    • 7.4.3. Pfizer's Arthrotec (diclofenac/misprostol)
    • 7.4.4. Boehringer Ingelheim/Abbott's Mobic (meloxicam)
    • 7.4.5. Pfizer's DayPro (oxarprozin)
    • 7.4.6. Pfizer's Xeljanz (tofacitinib)
  • 7.5. Unmet Needs in the Arthritic Pain Market
  • 7.6. Arthritic Pain Therapeutic Pipeline Analysis
    • 7.6.1. Eli Lilly/Incyte's Baricitinib
    • 7.6.2. Galapagos NV/AbbVie's Filgotinib (GLPG0634)
    • 7.6.3. Astellas'Peficitinib (ASP015K)
    • 7.6.4. Sanofi/Regeneron's Sarilumab (REGN88/SAR153191)
    • 7.6.5. Janssen/GSK's Sirukumab (CNTO136)
    • 7.6.6. Alder Biopharmaceuticals' Clazakizumab
    • 7.6.7. Epirus Biopharmaceuticals' BOW015(infliximab)
  • 7.7. Arthritic Pain Market Commentary

8. THE MIGRAINE MARKET

  • 8.1. Migraine Overview
  • 8.2. Epidemiology of Migraine
  • 8.3. The Therapeutic Management of Migraine
    • 8.3.1. Prophylactic Migraine Therapies
    • 8.3.2. Basic Analgesics Used in Migraine
    • 8.3.3. Ergot Alkaloid Derivatives Used in Migraine
    • 8.3.4. Triptans Used in Migraine
    • 8.3.5. Neuroleptics Used in Migraine
    • 8.3.6. Beta-Blockers Used in Migraine
  • 8.4. Leading Brand Products in the Migraine Market
    • 8.4.1. GSK's Imitrex/Imigran (sumatriptan)
  • 8.5. Impax Laboratories/AstraZeneca's Zomig (zolmitriptan)
    • 8.5.1. Merck's Maxalt (rizartriptan)
    • 8.5.2. Pfizer's Relpax (eletriptan)
    • 8.5.3. Pernix Therapeutics/Pozen's Treximet (sumatripatan/naproxen)
    • 8.5.4. Janssen's Topamax (topiramate)
    • 8.5.5. AbbVie's Depakote (divalproex)
    • 8.5.6. Allergan's Botox (onabotulinumtoxinA)
  • 8.6. Unmet Needs in the Migraine Market
  • 8.7. Migraine Therapeutics Pipeline Analysis
    • 8.7.1. CoLucid Pharmaceuticals' Lasmiditan (COL-144)
    • 8.7.2. Allergens' Semprana (dihydroergotamine)
    • 8.7.3. Avanir/OptiNose's AVP-825(sumatriptan intranasal powder)
    • 8.7.4. Trigemina's T1-001(oxytocin)
    • 8.7.5. Alder Biopharmaceuticals' ALD403
    • 8.7.6. Amgen's AMG 334
    • 8.7.7. Teva Pharmaceuticals' TEV-48125
    • 8.7.8. Eli Lilly's LY2951742
  • 8.8. Migraine Market Commentary

9. THE CANCER PAIN MARKET

  • 9.1. Cancer Pain Overview
  • 9.2. Epidemiology of Cancer Pain
  • 9.3. The Therapeutic Management of Cancer Pain
    • 9.3.1. Strong Opioids Used in Cancer Pain
    • 9.3.2. Weak Opioids Used in Cancer Pain
    • 9.3.3. NSAIDs and Acetaminophen Used in Cancer Pain
    • 9.3.4. Adjuvants Used in Cancer Pain
  • 9.4. Leading Brands in the Cancer Pain Market
    • 9.4.1. Teva's Actiq (oral transmucosal fentanyl citrate)
    • 9.4.2. Teva's Fentora (fentanyl buccal)
    • 9.4.3. Purdue's OxyContin (oxycodone)
    • 9.4.4. Galena Biopharma/ProStrakan's Abstral (fentanyl sublingual)
    • 9.4.5. Insys Therapeutics' Subsys (sublingual fentanyl)
  • 9.5. Unmet Needs in the Cancer Pain Therapeutics Market
  • 9.6. Cancer Pain Therapeutics Pipeline Analysis
    • 9.6.1. GW Pharmaceuticals' Sativex (GW-1000)
    • 9.6.2. Wex Pharmaceuticals' Tectin (tetrodotoxin)
    • 9.6.3. AcelRX Pharmaceuticals' ARX-02
  • 9.7. Cancer Pain Therapeutics Market Commentary

10. THE BACK PAIN MARKET

  • 10.1. Back Pain Overview
  • 10.2. Epidemiology of Back Pain
  • 10.3. The Therapeutic Management of Back Pain
    • 10.3.1. NSAIDs Used in Back Pain
    • 10.3.2. Transdermal Patches Used in Back Pain
    • 10.3.3. Local Anesthetics Used in Back Pain
    • 10.3.4. Opioids Used in Back Pain
    • 10.3.5. Tricyclic Antidepressants Used in Back Pain
    • 10.3.6. Muscle Relaxants Used in Back Pain
    • 10.3.7. Colchicine Used in Back Pain
    • 10.3.8. Anticonvulsants Used in Back Pain
  • 10.4. Leading Brand Products in the Back Pain Market
    • 10.4.1. Bayer's Aleve (naproxone)
    • 10.4.2. Novartis' Voltaren (diclofenac)
    • 10.4.3. Pfizer's Advil (ibuprofen)
    • 10.4.4. BMS' Efferalgan (acetaminophen)
    • 10.4.5. Johnson &Johnson's Tyenol (acetaminophen)
  • 10.5. Unmet Needs in the Back Pain Market
  • 10.6. Back Pain Pipeline Analysis
    • 10.6.1. Pfizer's Tanezumab
    • 10.6.2. Pfizer's ALO-02(oxycodone-naltrexone)
    • 10.6.3. Teva Pharmaceuticals' CEP-33237(Hydrocodone ER-Abuse Deterrent)
    • 10.6.4. Collegium Pharmaceuticals' Xtampza ER (Oxycodone ER)
    • 10.6.5. Mesoblast's MPC-016-ID
  • 10.7. Back Pain Market Commentary

11. PAIN THERAPEUTICS RESEARCH AND DEVELOPMENT TRENDS

  • 11.1. Introduction to Pain R&D: The Need for Change
  • 11.2. Overview of Clinical Trials
    • 11.2.1. The Triad of Successful Pain Clinical Trials
  • 11.3. Issues Surrounding Analgesic Clinical Trials
    • 11.3.1. Patient Selection
    • 11.3.2. Randomization, Stratification and Blinding
    • 11.3.3. Trial Duration
    • 11.3.4. Trial Comparator Drug Choice
    • 11.3.5. Trial Endpoint Choice
    • 11.3.1. Patient Dropout
    • 11.3.2. Missing Data
    • 11.3.3. Placebo Effect
  • 11.4. Biomarkers in R&D
    • 11.4.1. Predictive Biomarkers as Clinical Trial Surrogate Endpoints
    • 11.4.2. The Use of Biomarkers to Stratify Patients
    • 11.4.3. Potential Pain Biomarkers
    • 11.4.4. Personalized Medicine in Pain
  • 11.5. Analgesic Target Selection and Validation
  • 11.6. Animal Pain Models
  • 11.7. Experimental Pain Models in Healthy Humans
    • 11.7.1. UV-B Pain Model
    • 11.7.2. Heat/Capsaicin Sensitization and Intradermal Capsaicin Injection Models
    • 11.7.3. Multi-Modal, Multi-Tissue Model
    • 11.7.4. Quantitative Sensory Testing
  • 11.8. Functional Imaging Techniques
    • 11.8.1. Functional Magnetic Resonance Imaging (fMRI)
    • 11.8.2. Positron Emission Tomography (PET)
    • 11.8.3. Single-Photon Emission Computed Tomography (SPECT)
  • 11.9. Laser Doppler Flowmetry (LDF)
    • 11.9.1. US Health Agencies Findings and Recommendations for Change in Pain R&D
    • 11.9.2. Arrowhead's Recommendations for Maximizing Pain Therapeutics R&D
    • 11.9.3. The Future of Pain R&D
  • 11.10. FDA's Efforts to Combat Opioid Misuse and Abuse
    • 11.10.1. Abuse-Deterrent Formulations
    • 11.10.2. Abuse Liability and Safety/ Risk Evaluation and Mitigation Strategy (REMS)

12. UNMET NEEDS IN THE PAIN THERAPEUTICS MARKET

  • 12.1. Clinical Efficacy Of Today's Analgesics Need Improving
  • 12.2. Safety Profiles of Current Pain Therapeutics Are Often Unacceptable
  • 12.3. Opioid Misuse and Abuse
  • 12.4. Certain Pain Patient Populations are Neglected
  • 12.5. Improved Dosing Regimens
  • 12.6. Convenient Administration Routes
  • 12.7. The Validity of Animal Pain Models
  • 12.8. The Reliability of Pain Evaluation Models
  • 12.8.1. Lack of Stakeholder Education

13. PAIN THERAPEUTICS PIPELINE WATCH

  • 13.1. Introduction to the Pain Therapeutics Pipeline
  • 13.2. Targeted Therapies
    • 13.2.1. Pfizer's Tanezumab (PF-4383119)
    • 13.2.2. Janssen's Fulranumab
  • 13.3. Nav Ion Channel Modulators
    • 13.3.1. Convergence Pharmaceuticals' CNV1014802
    • 13.3.2. Xenon/Teva's TV-45070
    • 13.3.3. Nektar's NKTR-171
    • 13.3.4. Xenon/Genentech's GDC-0276
    • 13.3.5. Pfizer's NAV1.7/1.8 Inhibitors
  • 13.4. Transient Receptor Potential (TPR) Channel Modulators
    • 13.4.1. TRPV1. Agonists
    • 13.4.2. Sorrento Therapeutics' Resiniferatoxn (RTX)
    • 13.4.3. TRP Antagonists
  • 13.5. Purinoreceptor (P2X3 Receptor) Antagonists
    • 13.5.1. Afferent Pharmaceuticals P2X3 Program
  • 13.6. Glutumate Receptor Antagonists
    • 13.6.1. NMDA-Receptor Antagonists
    • 13.6.2. NDMA and Opioid Receptor Overlap
    • 13.6.3. Dual Mu-Opioid Agonist and Nor Epinephrine Reuptake Inhibitors
  • 13.7. Imidazoline l2 Receptors
  • 13.8. Abuse-Deterrent Opioids
    • 13.8.1. Collegium Pharmaceuticals' Xtampza ER (oxycodone DETERx)
    • 13.8.2. Pfizer's ALO-02 (oxycodone/naltrexone)
    • 13.8.3. Teva Pharmaceuticals' CEP-33237(Hydrocodone ER)
    • 13.8.4. Microglia Inhibitors

14. ANALYSIS OF THE PAIN THERAPEUTIC MARKET

  • 14.1. Summary of Arrowhead's Pain Therapeutics Analysis, 2015
  • 14.2. Leading Pain Therapeutic Products of 2014
  • 14.3. Leading Pain Therapeutics Drug Classes of 2014
  • 14.4. Leading Pain Therapeutics Drug Class Products of 2014
    • 14.4.1. COX-2 Inhibitors: Pfizer's Celebrex (celecoxib)
    • 14.4.2. NSAIDs: Novartis' Voltaren (diclofenac)
    • 14.4.3. Local Anesthetics: Pacira's Exparel (bupivacaine liposome Injection)
    • 14.4.4. Opioids: Purdue's OxyContin (oxycodone)
    • 14.4.5. Triptans: Pfizer's Relpax (eletriptan)
    • 14.4.6. Non-traditional: Pfizer's Lyrica (pregabalin)
  • 14.5. Pfizer: Arrowhead's Leading Pain Therapeutics Company of 2014/2015
  • 14.6. SWOT Analysis of the Pain Therapeutics Market, 2015
  • 14.7. Financial Forecast of the Pain Therapeutics Market
    • 14.7.1. Financial Forecast of the Branded Pain Therapeutic Market
  • 14.8. Arrowhead's NSAID Market Outlook
    • 14.8.1. Drivers and Constraints of the NSAID Market
    • 14.8.2. Financial Forecast of the NSAID Market
  • 14.9. Arrowhead's Cox-2 Market Outlook
    • 14.9.1. Drivers and Constraints of the COX-2 Market
    • 14.9.2. Financial Forecast of the COX-2 Market ($m)
  • 14.10. Arrowhead's Opioid Market Outlook
    • 14.10.1. Drivers and Constraints of the Opioid Market
    • 14.10.2. Financial Forecast of the Opioid Market
    • 14.10.3. Arrowhead's Triptan Market Outlook
    • 14.10.4. Drivers and Constraints of the Triptan Market
    • 14.10.5. Financial Forecast of the Triptan Market
    • 14.10.6. Arrowhead's Non-Traditional/Adjuvant Market Outlook
    • 14.10.7. Drivers and Constraints of the Non-Traditional/Adjuvant Pain Therapeutic Market
    • 14.10.8. Financial Forecast of the Non-Traditional/Adjuvant Market
  • 14.11. Arrowhead's Local Anesthetics Market Outlook
    • 14.11.1. Drivers and Constraints of the Local Anesthetic Market
    • 14.11.2. Financial Forecast of the Local Anesthetics Market
  • 14.12. Summary of the Future Global Pain Therapeutic Market

15. COMPANY BRIEFS

  • 15.1. Abbvie Inc.
  • 15.2. Acelrx Pharmaceuticals Inc.
  • 15.3. Acorda Therapeutics Inc.
  • 15.4. Adynxx
  • 15.5. Alder Biopharmaceuticals Inc.
  • 15.6. Allergan
  • 15.7. Amgen Inc.
  • 15.8. Astellas Pharmaceuticals Inc.
  • 15.9. AstraZeneca
  • 15.10. Avanir Pharmaceuticals Inc.
  • 15.11. Biogen Inc.
  • 15.12. Biosciences Delivery International Inc.
  • 15.13. COLLEGIUM Pharmaceutical Inc.
  • 15.14. Colucid Pharmaceuticals Inc.
  • 15.15. Daiichi Sankyo Company Ltd.
  • 15.16. Depomed Inc.
  • 15.17. Durect Corporation
  • 15.18. Eli Lilly and Company
  • 15.19. Endo Pharmaceuticals Inc.
  • 15.20. Epirus Biopharmaceuticals
  • 15.21. Galapagos NV
  • 15.22. Galena Biopharma
  • 15.23. GW Pharmaceuticals PLC
  • 15.24. Horizon Pharma PLC
  • 15.25. Hospira Inc.
  • 15.26. Incyte Corporation
  • 15.27. Immune Pharmaceuticals
  • 15.28. Impax Laboratories
  • 15.29. Insys Therapeutics Inc.
  • 15.30. Johnson & Johnson
  • 15.31. Meda AB
  • 15.32. Mesoblast Ltd.
  • 15.33. Novartis International AG
  • 15.34. Optinose US Inc.
  • 15.35. Pacira Pharmaceuticals Inc.
  • 15.36. Pernix Therapeutics Holdings Inc.
  • 15.37. Pfizer Inc.
  • 15.38. Proove Biosciences Inc.
  • 15.39. Pozen Inc.
  • 15.40. Prostrakan Group
  • 15.41. Purdue Pharmaceuticals LP
  • 15.42. Regeneron Pharmaceuticals Inc.
  • 15.43. Sanofi
  • 15.44. Spinifex Pharmaceuticals Pty Ltd.
  • 15.45. Teva Pharmaceuticals Industries Ltd.
  • 15.46. Theravance Biopharma
  • 15.47. Tonix Pharmaceuticals
  • 15.48. Trevena Inc.
  • 15.49. Trigemina Inc.
  • 15.50. WEX Pharmaceuticals
  • 15.51. Yichang Humanwell Pharmaceutical Co. Ltd.

16. BIBLIOGRAPHY

LIST OF TABLES

  • Table 1: Pain Incidence Forecast in the Seven Major Markets, 2008-2020
  • Table 2: Current Preregistration Pain Therapeutics Pipeline, Oct 2015
  • Table 3: Comparison of the Global Pain Therapeutics Market ($m) Revenue by Analgesic Class, 2015 and 2020
  • Table 4: Characteristics and Treatment of Acute versus Chronic Pain
  • Table 5: Heritability Link in a Range of Diseases where Pain is a Predominant Factor
  • Table 6: Single Nucleotide Polymorphisms (SNPs) Suggested to Affect Human Pain Sensitivity
  • Table 7: Incidence of Pain Compared to Other Major Conditions in the US
  • Table 8: Incidence of Painful Conditions in US Households
  • Table 9: Ranking of the Global Leading Disability Conditions
  • Table 10: Annual Cost of Treating Back Pain by European Country
  • Table 11: WHO Guidelines for Pain Management
  • Table 12: Surgery Incidence Forecast in the Seven Major Markets, 2008-2020
  • Table 13: Postoperative Acute Pain Incidence Forecast in the Seven Major Markets, 2008-2020
  • Table 14: Late-Stage and Phase II Postoperative Pain Therapeutics Pipeline, Oct 2015
  • Table 15: Common Etiologies Associated with Neuropathic Pain
  • Table 16: Neuropathic Pain Incidence Forecast in the Seven Major Markets, 2008-2020
  • Table 17: Neuropathic Pain Therapeutics
  • Table 18: Summary of Branded Therapeutics FDA Approved for Neuropathic Pain
  • Table 19: Late-Stage and Phase II Neuropathic Pain Therapeutics Pipeline, Oct 2015
  • Table 20: Fibromyalgia Incidence Forecast in the Seven Major Markets, 2008-2020
  • Table 21: Late-Stage and Phase II Fibromyalgia Pain Therapeutics Pipeline, Oct 2015
  • Table 22: Arthritis Incidence Forecast in the Seven Major Markets, 2008-2020
  • Table 23: Late-Stage and Phase II Arthritic Pain Therapeutics Pipeline, Oct 2015
  • Table 24: Incidence Rate of Migraine (%) by Gender in the Seven Major Markets
  • Table 25: Migraine Incidence Forecast in the Seven Major Markets, 2008-2020
  • Table 26: Common Analgesics Used for Mild Migraine
  • Table 27: Ergot Alkaloid Derivatives Used for Migraine
  • Table 28: Triptans Used for Migraine
  • Table 29: Late-Stage and Phase Migraine Pain Therapeutics Pipeline, Oct 2015
  • Table 30: Crude Incidence Rate of Cancer by Gender in the Seven Major Markets
  • Table 31: Cancer Incidence Forecast in the Seven Major Markets, 2008-2020
  • Table 32: Cancer Pain Incidence Forecast in the Seven Major Markets, 2008-2020
  • Table 33: The Oral and Paraental Equivalences and Relative Potency of Opioids Compared with Morphine
  • Table 34: Adjuvant Therapeutics Used in Cancer Pain Management
  • Table 35: Late-Stage and Phase II Cancer Pain Therapeutics Pipeline, Oct 2015
  • Table 35: Late-Stage and Phase II Cancer Pain Therapeutics Pipeline, Oct 2015
  • Table 36: Low Back Pain Incidence Forecast in the Seven Major Markets, 2008-2020
  • Table 37: Late-Stage and Phase II Back Pain Therapeutics Pipeline, Oct 2015
  • Table 38: Potential Pain Biomarkers
  • Table 39: Pain Therapeutics Investigated by fMRI
  • Table 40: Pain Therapeutics Pipeline, Oct 2015
  • Table 41: Sodium Channel Modulators Pipeline, Oct 2015
  • Table 42: Summary of Branded Analgesics Analyzed by Arrowhead Publishers, 2015 Table 43: Top-10 Selling Branded Analgesics, 2014 Revenues ($m)
  • Table 44: Revenues of the 2014 and 2013 Top-Selling Analgesics by Drug Classification ($m)
  • Table 45: Global Leading Branded Pain Therapeutic Revenue History ($m), 2009-2014
  • Table 46: Summary of Arrowhead's Key Pipeline Pain Therapeutics Candidates, 2015
  • Table 47: Global Leading Branded Pain Therapeutic Revenue Forecast ($m), 2015-2020
  • Table 48: Financial Forecast of the NSAID Global Market ($m), 2014-2020
  • Table 49: Financial Forecast of the COX-2 Global Market ($m), 2014-2020
  • Table 50: Financial Forecast of the Opioid Global Market ($m), 2014-2020
  • Table 51: Financial Forecast of the Triptan Global Market ($m), 2014-2020
  • Table 52: Financial Forecast of the Non-Traditional/Adjuvant Global Market ($m), 2014-2020
  • Table 53: Financial Forecast of Local Anesthetics Global Market ($m), 2014-2020
  • Table 54: Total Global Leading Branded Pain Therapeutic Market Forecast ($m) by Drug Class, 2014-2020
  • Table 55: Total Global Pain Therapeutics Market Revenue Forecast ($bn), 2014-2020

LIST OF FIGURES

  • Figure 1: Pain Incidence Forecast in the Seven Major Markets, 2008-2020
  • Figure 2: Pain Incidence Forecast in the Seven Major Markets, 2015 and 2020
  • Figure 3: Unmet Needs in the Pain Therapeutics Market
  • Figure 4: Analgesic Drug Class Share of the Global Pain Therapeutics Market, 2015
  • Figure 5: Analgesic Drug Class Share of the Global Pain Therapeutics Market, 2020
  • Figure 6: Schematic Diagram of the Pain Pathway
  • Figure 7: Schematic Diagram of Referred Pain Pathways Involved in an Ischemic Cardiac Attack
  • Figure 8: Examples of Pain Evaluation Models
  • Figure 9: Leading Causes of Pain in the US
  • Figure 10: Surgery Incidence Forecast in the Seven Major Markets, 2008-2020
  • Figure 11: Postoperative Acute Pain Incidence Forecast in the Seven Major Markets, 2008-2020
  • Figure 12: World Federation of Societies of Anesthesiologists (WFSA) Analgesic Ladder
  • Figure 13: PROSPECT Postoperative Pain Management Algorithm
  • Figure 14: TRV130's Hypothesized Mode of Action compared with Morphine
  • Figure 15: Neuropathic Pain Incidence Forecast in the Seven Major Markets, 2008-2020
  • Figure 16: NIH Algorithm for Managing Neuropathic Pain
  • Figure 17: Fibromyalgia Painful Points within the Human Body
  • Figure 18: Fibromyalgia Incidence Forecast in the Seven Major Markets, 2008-2020
  • Figure 19: Treatment Algorithm for Fibromyalgia
  • Figure 20: Arthritis Incidence Forecast in the Seven Major Markets, 2008-2020
  • Figure 21: Arthritis Therapeutic Treatment Algorithm
  • Figure 22: Migraine Incidence Forecast in the Seven Major Markets, 2008-2020
  • Figure 23: European Federation of Neurological Societies (EFNS) 2009 Migraine Treatment Algorithm
  • Figure 24: CoLucid's Lasmiditan Migraine Development Program Timeline
  • Figure 25: Cancer Incidence Forecast in the Seven Major Markets, 2008-2020
  • Figure 26: Cancer Pain Incidence Forecast in the Seven Major Markets, 2008-2020
  • Figure 27: WHO's Three-Step ‘Analgesia Ladder' for Cancer Pain Management
  • Figure 28: Low Back Pain Incidence Forecast in the Seven Major Markets, 2008-2020
  • Figure 29: Back Pain Treatment Algorithm
  • Figure 30: The Triad of Successful Pain Clinical Trials
  • Figure 31: Schematic Diagram of Blood Oxygenation Level Dependent (BOLD) Concept in MRI
  • Figure 32: A Proposed New Analgesic Drug Development Pathway
  • Figure 33: Drug Overdose Related Deaths Involving Opioids in the US, 1999-2012 Figure 34: SWOT Analysis of the Pain Therapeutics Market, 2015
  • Figure 35: Global Leading Branded Pain Therapeutic Revenue Forecast ($m), 2009-2020
  • Figure 36: Financial Forecast of the NSAID Global Market ($m), 2014-2020
  • Figure 37: Financial Forecast of the COX-2 Global Market ($m), 2014-2020
  • Figure 38: Financial Forecast of the Opioid Global Market ($m), 2014-2020
  • Figure 39: Financial Forecast of the Triptan Global Market ($m), 2014-2020
  • Figure 40: Financial Forecast of the Non-Traditional/Adjuvant Global Market ($m), 2014-2020
  • Figure 41: Financial Forecast of Local Anesthetics Global Market ($m), 2009-2015
  • Figure 42: Total Global Leading Branded Pain Therapeutics Market Forecast ($m) by Drug Class, 2014-2020
  • Figure 43: Total Global Leading Branded Pain Therapeutics Market Revenue Forecast ($m), 2014-2020
  • Figure 44: Total Global Pain Therapeutics Market Revenue Forecast ($bn), 2014-2020
Back to Top